Kneevoice

Market position

Kneevoice describes its product as poised to be the first non-invasive cartilage auscultation device for assessing the degree of knee cartilage damage, and coverage of its seed round cites a $15 billion US market opportunity for knee diagnosis.

The company contrasts its approach with X-ray, CT and MRI imaging, which it says make precise and dynamic auscultation of cartilage damage difficult, and with workflows in which patellofemoral osteoarthritis data is interpreted by specialists rather than the treating physician. Kneevoice emphasizes a non-invasive, pain-free, low-cost, repeatable in-office assessment producing an easy-to-read objective score.

Technology

The system uses patented, non-invasively placed knee sensors that capture joint sounds, vibrations and position during 8-10 knee flexions. Digital patellofemoral audio-arthrography data is processed with neural networks and advanced sound and vibration analysis; the platform compares new data against existing data to refine accuracy over time and automatically generates a cartilage damage score report along with an audio recording for further evaluation.

Go-to-market

The device is intended for point-of-care use in physician practices and physical therapy clinics, supported by collaboration agreements with orthopedic groups such as the Michigan Knee Institute and Samimi Orthopedic Group and a partnership with Cedars-Sinai Kerlan-Jobe; commercial launch was planned to follow FDA clearance.

Orthopedic surgeons, general medical practitioners and physical therapists assessing knee cartilage, with planned extension to patients and athletes monitoring knee health remotely, including team sports settings.

Geography

Headquartered in Santa Monica, California, with clinical advisors and testimonial physicians in Minnesota, New York and Colorado; an early multi-country clinical trial is referenced in the company timeline.

History

The company's published timeline describes a friends-and-family/pre-seed priced round in 2019-2020 alongside initial MVP tests, formation of an advisory board, a first multi-country clinical trial and granted patents. From 2021 to 2023 it raised convertible notes, held FDA pre-submissions, partnered with Cedars-Sinai Kerlan-Jobe, froze and cleared its design, made FDA-related key hires and won gold in Pepperdine University's "Most Fundable Companies" competition. In 2024 it raised seed/convertible note financing, conducted further FDA pre-submissions, signed collaboration agreements with the Michigan Knee Institute and Samimi Orthopedic Group, and started medical trials. Plans set out for 2025 included closing the seed round, finalizing medical trials, FDA submission and clearance, and launching a commercial phase; FDA 510(k) clearance was announced in February 2026.